Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM]

Autor: Davis, AG, Wasserman, S, Maxebengula, M, Stek, C, Bremer, M, Daroowala, R, Aziz, S, Goliath, R, Stegmann, S, Koekemoer, S, Jackson, A, Lai Sai, L, Kadernani, Y, Sihoyiya, T, Liang, CJ, Dodd, L, Denti, P, Crede, T, Naude, J, Szymanski, P, Vallie, Y, Banderker, I, Moosa, S, Raubenheimer, P, Lai, RPJ, Joska, J, Nightingale, S, Dreyer, A, Wahl, G, Offiah, C, Vorster, I, Candy, S, Robertson, F, Meintjes, E, Maartens, G, Black, J, Meintjes, G, Wilkinson, RJ

Background: Tuberculous meningitis (TBM) is the most lethal form of tuberculosis with a mortality of ~50% in those co-infected with HIV-1. Current antibiotic regimens are based on those known to be effective in pulmonary TB and do not account for the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::1bb9efb75183887e6dc921dfe994c792
http://hdl.handle.net/10044/1/89369

A young adult with leptospirosis associated acute inflammatory demyelinating polyneuropathy.

Autor: Bagula H; Department of Internal Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Banderker I; Department of Internal Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Moosa MS; Department of Internal Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

Publikováno v: Southern African journal of infectious diseases [S Afr J Infect Dis] 2023 Dec 21; Vol. 38 (1), pp. 569. Date of Electronic Publication: 2023 Dec 21 (Print Publication: 2023).